India’s CDMO Sector Poised for Growth as Pharma Diversifies Beyond China
The global pharmaceutical supply chain is undergoing a structural realignment as multinational companies seek to reduce their dependence on Chinese manufacturing. This shift is positioning Indian Contract Development and Manufacturing Organisations (CDMOs) as the preferred alternative for global drugmakers seeking stability and regulatory reliability.
India Emerges as the Strategic Alternative to China
The global CDMO landscape is witnessing a significant pivot, driven by intensifying regulatory scrutiny of Chinese giants like WuXi AppTec. According to Sivaramakrishnan Chittor, CFO of Sai Life Sciences, the move away from China is not a sudden reaction but a process that began nearly two years ago.
The inclusion of certain entities in regulatory lists has provided further clarity for global pharma companies to diversify their manufacturing footprints. Indian CDMOs are aggressively positioning themselves to capture this market by scaling up operations and committing significant capital expenditure (Capex) to meet rising demand.
Sai Life Sciences: Driving Growth Through Large Pharma
The shift in manufacturing preferences is clearly visible in the revenue models of leading Indian players. At Sai Life Sciences, the contribution from global "Big Pharma" has nearly doubled, rising from 28% to 49% over the last four years.
The company currently works with 19 of the world's top 25 pharmaceutical companies. A critical trend noted by management is the evolution of India's role: while many global firms previously used Indian partners primarily for clinical supplies, there is a decisive move toward using India for large-scale commercial manufacturing. This is evidenced by the increase in Phase III and pre-registration molecules in Sai Life Sciences' pipeline, which grew from six to eleven molecules recently.
Aggressive Capex and Financial Outlook
To capitalize on this landmark opportunity, Sai Life Sciences has announced a substantial expansion plan. The company intends to invest between ₹1,100 crore and ₹1,300 crore in capacity expansion by FY27. This investment will be funded through a combination of internal accruals and debt, maintaining a healthy balance sheet.
Despite the massive potential, the industry remains mindful of the regulatory complexities involved in transferring pharmaceutical products. Because manufacturing shifts require stringent regulatory approvals and long product transfer timelines, the full impact of this diversification may not be immediate. Consequently, Sai Life Sciences has maintained its steady revenue growth guidance of 15-20% CAGR.
A Long-term Structural Shift
The transition from Chinese manufacturing to Indian alternatives is expected to be a gradual, multi-year process rather than a quick windfall. As new production facilities come online—with some capacity expected to be operational by the end of this financial year—Indian CDMOs are setting the stage for long-term dominance in the global drug supply chain.
Key Takeaways
- Strategic Diversification: Global pharma companies are actively moving manufacturing away from China toward India to mitigate regulatory and supply chain risks.
- Commercial Scaling: The Indian CDMO sector is transitioning from providing clinical trial supplies to managing large-scale commercial manufacturing for global innovators.
- Significant Investment: Leading players like Sai Life Sciences are committing up to ₹1,300 crore in Capex to expand capacity and meet the growing demands of "Big Pharma."